CCND1 and cervical carcinoma: A promising new drug currently entering a peer-reviewed clinical trial for cervical cancer is sulfur heteroarotinoid A2 (SHetA2, NSC 726189), a small molecule flexible heteroarotinoid (Flex-Het) which targets cyclin D1 for degradation [12].